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A B S T R A C T
Background
Mass treatment with albendazole, co-administered with another antifilarial drug, is being promoted as part of a global programme to
eliminate lymphatic filariasis.
Objectives
To assess the effects of albendazole on patients or populations with filarial infection, and on morbidity in patients with filarial infection;
and to assess the frequency of adverse events for albendazole both given singly or in combination with another antifilarial drug
(diethylcarbamazine or ivermectin).
Search strategy
We searched the Cochrane Infectious Disease Group’s trial register (September 2003), the Cochrane Central Register of Controlled
Trials (The Cochrane Library Issue 3, 2003), MEDLINE (September 2003), EMBASE (September 2003), LILACS (September 2003);
and checked the reference lists and contacted experts, international organizations, and a pharmaceutical company.
Selection criteria
Randomized and quasi-randomized controlled trials of albendazole singly or in combination with anti-filarial drugs in people or
populations with lymphatic filariasis.
Data collection and analysis
Two reviewers assessed eligibility and trial methodological quality. We calculated relative risks (RR) with 95% confidence intervals (CI)
for binary outcomes, and where appropriate, combined them in a meta-analysis using the fixed effect model or random effects model.
Main results
Four small studies met the inclusion criteria (a total of 2473 children and adults, of whom 536 had detectable microfilariae). No effect
of albendazole on microfilaraemia was demonstrated in two studies (placebo controlled, RR 0.97, 95% CI 0.87 to 1.09, n = 195).
When compared to ivermectin, albendazole performedworse (RR 0.84, 95% CI 0.72 to 0.98, 2 studies of patients initially microfilariae
positive, n = 198). When compared to diethylcarbamazine, no statistically significant difference was detected, but numbers were small
(n = 56).
Two studies compared albendazole plus ivermectin to ivermectin alone on the presence ofmicrofilaraemia. Results weremixed: one study
showed the combination to be more effective (RR 0.27, 95% CI 0.11 to 0.70, n = 52), but the other did not demonstrate a statistically
significant difference (RR 1.04, 95% CI 0.87 to 1.25, n = 145). A further study compared albendazole plus diethylcarbamazine to
diethylcarbamazine alone and did not demonstrate a difference on microfilaraemia prevalence. No study examined the effects of the
drugs on adult worms.
Authors’ conclusions
There is insufficient reliable research to confirm or refute whether albendazole alone, or co-administered with diethylcarbamazine or
ivermectin, has an effect on lymphatic filariasis.
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B A C K G R O U N D
Epidemiology
Lymphatic filariasis is a parasitic infection of threadlike, filarial
worms, affecting about 120 million people in more than 80 coun-
tries (Michael 1996; WHO 2000). Bancroftian filariasis, caused
by infection with Wuchereria bancrofti occurs in tropical regions
of Asia, Africa, China, the Pacific islands, and in parts of the
Caribbean and South America. Brugian filariasis is less common,
with Brugia malayi occurring in parts of Asia, and Brugia timori
in Indonesia (FGN 1996).
Filariasis is transmitted by mosquitoes from a number of genera
(including Culex, Anophelines,Mansonia,Ochlerotatus, and Aedes)
(Burkot 2002). Female mosquitoes transmit the disease. They are
infected when they take blood meals from people with microfi-
lariae, early stage larvae. The larvae develop for about 12 to 15
days in the mosquito to a mature larval stage (Scott 2000), which
can establish itself after entering the skin and the lymphatic vessels
following a subsequent blood meal. When the mosquito infects
the human host, the larvae migrate to the lymph vessels and de-
velop into adult worms, where male and female worms pair. They
later produce microfilariae that migrate to the blood and cause
microfilaraemia, that is, microfilariae in the blood. The time be-
tween being infected and adult worms producing microfilaraemia
is estimated to be about 12 months (Mahoney 1971).
Microfilariae move in and out of circulating peripheral blood ac-
cording to a daily cycle. In most species, microfilarial levels peak
during the night between 10 pm to 4 am (Simonsen 1997) − a
time when mosquito vectors are actively feeding. In Fiji, Polyne-
sia, and the Philippines, some strains ofW. bancrofti microfilariae
peak during the day (Scott 2000).
Clinical features
Many people with filariasis may be asymptomatic most of the
time. However, even people without clinical symptoms often have
lymphatic changes, including lymphangiectasia (widening of the
lymphatic vessels), and thickening of the spermatic cord (Addiss
2000; Dreyer 2000), which can be detected through imaging stud-
ies. Clinical symptoms and signs include hydrocoele (excess fluid
inside the scrotal sac), lymphoedema (swelling and enlargement
of affected areas of the body), and elephantiasis (long standing en-
largement and swelling of the limbs, scrota, or breasts associated
with skin thickening).
Historically, filarial infection has been diagnosed by examining a
blood smear for microfilariae. But even if blood is taken at night,
not all infections are detected because microfilarial levels are very
low in many people. Antigen assays, which became available for
field use during the 1990s, are more sensitive and can be used for
blood collected during the day or night (Weil 1997) because they
indicate the presence of the adult worm and do not depend on
the temporal presence of microfilariae. Ultrasound imaging can
demonstrate the presence of live adult worms (Dreyer 1995).
How the filarial worm causes disease is not well understood. The
followinghave beenproposed: adultworms living in anddamaging
lymph vessels; immunologic reactions to the presence and death of
filarial worms; secondary infections of affected areas, which con-
tribute significantly to both acute and chronic disease manifesta-
tions (Dreyer 2000). Researchers have also suggested that toxins
released by Wolbachia (endosymbiotic bacteria found within the
cells of filarial worms) cause disease (Taylor 2001). Some or all of
these processes may be important.
Control
Control strategies aim to reduce microfilariae in the community
to levels that prevent transmission (Ottesen 1997; Ottesen 1999).
Treatment of individuals with clinical disease is generally only par-
tially effective (at least in part because there is no drug that reli-
ably kills the ’macrofilariae’, the adult worms). Mass drug admin-
istration programmes therefore aim for a sustainable reduction
in community microfilarial loads below a critical threshold, or a
complete clearance of microfilariae, to have an appreciable impact
on transmission. The ’Global Alliance to Eliminate Lymphatic Fi-
lariasis’ recommend yearly, single-dose, two-drug regimens (either
albendazole plus diethylcarbamazine (DEC); or albendazole plus
ivermectin), for at least five years (corresponding to the reproduc-
tive lifespan of the adult worm) to prevent transmission. How-
ever, the critical threshold below which no further transmission
will take place is unclear, and may depend on the vector species
in the locality. Some mosquitoes (for example, Aedes polynesiensis,
some culicine mosquitoes in India and the Americas) may be more
efficient at lower microfilarial densities (a process known as lim-
itation). Higher treatment coverage for longer periods, or other
strategies such as vector control, may be required in areas where
these vectors are responsible for a high proportion of transmission
(Burkot 2002; Pichon 2002).
Ivermectin and DEC both kill microfilariae, and DEC may have
some temporary sterilizing effect or actually kill adult worms, so
one treatment with either drug can affect microfilarial levels for
many months. Reductions of 90% from pre-treatment microfilar-
ial levels have been seen after single dose DEC or ivermectin, even
one year after treatment (Ottesen 1999). The impact on trans-
mission can be enhanced, if currently available antifilarial drugs
demonstrate a killing or sterilizing effect on adult worms, in addi-
tion to their effect on microfilariae. There are concerns that over
reliance on a limited range of drugs may eventually cause resis-
tance, although there is little direct evidence that this is currently
a problem in filariasis (Barat 1997; Geerts 2001).
It has been observed that some infected people lose their micro-
filariae in the absence of treatment (Vanamail 1990). However,
overall microfilarial prevalence rates are believed to be relatively
stable over time in endemic communities in the absence of com-
munity treatment (Meyrowitsch 1995), with new, microfilaraemic
infections replacing those whose microfilaraemia subsides (Vana-
mail 1990; Weil 1999). Nevertheless, lymphatic filariasis has been
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eliminated from some areas such as the Choiseul Island (Solomon
Islands) and Australia using vector control methods (Pichon 2002;
Burkot 2002), and parts of China using DEC-medicated salt and
other DEC regimens (Gelband 1994).
Diethylcarbamazine and ivermectin
DEC has been in use for filariasis for more than 50 years. In the
early years of control the recommended regimen for DEC was 6
mg/kg daily for 12 days (WHO 1984). Later, clinical and com-
munity trials determined that single doses given at various inter-
vals −weekly, monthly, annually, and biannually − were equally
effective (Eberhard 1989; Andrade 1995; Simonsen 1995). There
is reasonable evidence from ultrasound and clinical observations
that DEC kills some adult worms (macrofilariae) after single doses
(Figueredo-Silva 1996; Noroes 1997; Addiss 2000).
Ivermectin is used for the treatment and community control of
onchocerciasis (which is caused by another filarial worm, On-
chocerca volvulus) and more recently has been effective in com-
munity control programs for lymphatic filariasis (Cartel 1990;
Coutinho 1994; Cao 1997). It can be used in many places, but
is particularly important in areas where both onchocerciasis and
lymphatic filariasis coexist, because DEC can cause eye damage
if given to individuals with onchocerciasis. However, recent ul-
trasound studies suggest that adult worms are not killed by iver-
mectin, even at high doses over a period of six months (Dreyer
1996; Addiss 2000).
Adverse effects of antifilarial drugs can be serious (though almost
never fatal) and prevent people from completing treatment. The
most serious appear to be due to a host immunologic reaction to
the dying worms (WHO 1984; Dreyer 1994). These effects in-
clude fever, headache, malaise, muscle pain, and blood in urine.
Local effects include localized pain, tender nodules, lymphadenitis
(inflammation of the lymph nodes), and lymphangitis (inflamma-
tion of lymph vessels) (Addiss 2000).
Albendazole
Albendazole has been used widely to treat intestinal parasites since
the late 1980s and may have a potential role in lymphatic filar-
iasis control (Ottesen 1999). A report from an informal consul-
tation organized by the World Health Organization suggests that
albendazole in repeated high doses has a killing or sterilizing effect
on adults ofW. bancrofti (CDS/FIL 1998; Sri Lanka (Jaya1993)).
However, the data in the report are scanty and it remains unclear
whether adding albendazole to eitherDECor ivermectin improves
cure, prevents further transmission, or influences the occurrence
of adverse events. A narrative review by Horton 2000 from the
company that manufactures albendazole did not demonstrate that
adding albendazole to either drug increased the frequency or sever-
ity of adverse events. The company manufacturing albendazole
state that this drug does not have a role in morbidity management
− it will not treat the symptoms in people already affected by filar-
iasis (GSK 2003) − but at least one trial has considered the effec-
tiveness of albendazole in reducing both disease progression and
incidence of new symptoms (such as hydrocoele) (Ghana (Dunyo
2000)). We therefore include this as a secondary outcome.
In this review, we aim to summarize the evidence for the effects
of albendazole alone or in combination with DEC or ivermectin
in both the individual treatment and transmission control of lym-
phatic filariasis.
O B J E C T I V E S
(1) To assess the effects of albendazole on patients or populations
with filarial infection.
(2) To assess the effects of albendazole on morbidity among pa-
tients with filarial infection (incidence of new disease or progres-
sion of existing symptoms)
(3) To assess the frequency of adverse events for albendazole both
given singly or in combinationwith another antifilarial drug (DEC
or ivermectin).
C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
• Randomized controlled trials.
• Cluster randomized controlled trials.
• Quasi-randomized controlled trials (controlled clinical trials
with non-randomized methods of treatment allocation such as
alternate allocation).
Types of participants
• Adults or children with filarial infection defined by (1) the pres-
ence of microfilariae parasites in the blood, (2) filarial antigens
in the blood, or (3) ultrasound detection of adult worms in
lymphatic vessels.
• Populations normally resident in endemic communities and
who are eligible for treatment regardless of microfilaraemia sta-
tus (community trials).
Types of intervention
• Albendazole alone versus placebo.
• Albendazole alone versus DEC.
• Albendazole alone versus ivermectin.
• Albendazole plus DEC versus DEC (DEC dose and regimen
same in both arms).
• Albendazole plus ivermectin versus ivermectin (ivermectin dose
and regimen same in both arms).
Types of outcome measures
Primary
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• Microfilaraemia (detectable microfilariae).
• Macrofilaria viability (live adult worms detected by ultrasound).
• Microfilarial density.
• Community microfilarial density (in mass treatment trials).
• Antigenaemia prevalence or density.
Secondary (clinical disease)
• Acute filariasis (fever combinedwith clinical evidence of inflam-
mation of the lymphatic system, as defined by trial authors).
• Appearance of hydrocoele or lymphoedema.
• Reduction in size of hydrocoele or lymphoedema.
Adverse events
• Any adverse events that prevent daily activities or require hos-
pitalization.
• Systemic adverse events (for example, fever, headache, malaise,
myalgia, or haematuria).
• Local adverse events (for example, localized pain and inflam-
mation, tender nodules, lymphadenitis, or lymphangitis).
S E A R C H S T R A T E G Y F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: search strategy
We attempted to identify all relevant studies regardless of
language or publication status (published, unpublished, in press,
and in progress).
We used the following search terms for all trial registers
and databases: filariasis; lymphatic filariasis; elephantiasis;
lymphoedema; Wuchereria bancrofti; Brugia malayi; Brugia
timori; filaricides; diethylcarbamazine; banocide; carbamazine;
hetrazan; luxuran; ivermectin; mectizan; benzimidazole;
albendazole; metiazol; and valbazen.
We searched the Cochrane Infectious Diseases Group’s trials
register up to September 2003 (full details of the Cochrane
Infectious Diseases Group’s methods are published in The
Cochrane Library in the section on Collaborative Review
Groups) and the Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library Issue 3, 2003).
We searched the following electronic databases using the search
strategy defined by The Cochrane Collaboration (Clarke 2003):
MEDLINE (1966 to September 2003); EMBASE (1980 to
September 2003); and LILACS (www.bireme.br; 1982 to
September 2003).
To help identify unpublished and ongoing trials, we held
meetings with representatives of the World Health Organization
and GlaxoSmithKline (the company producing albendazole),
and contacted experts including David Molyneux, Janis Lazdins,
Vasanthapura Kumaraswami, and Graham White.
We checked the reference lists of existing reviews and of all
identified trials for further reports.
M E T H O D S O F T H E R E V I E W
Study selection
One reviewer (Henry Ejere (HE) or Julia Critchley (JC)) screened
titles and abstracts identified from the search strategy. We
retrieved hard copies of the published or unpublished trial reports
potentially relevant to the review for further assessment. We used
a predesigned eligibility form to select studies and included trials
that met the inclusion criteria (HE or JC and Paul Garner (PG)).
We resolved disagreements through discussion.
Assessment of the methodological quality
Two reviewers (HE or JC and PG) independently assessed
trials according to predefined quality criteria in relation to
generation of allocation sequence; concealment of allocation;
blinding of participants, investigators, and outcome assessors;
and completeness of follow up (less than 10% loss to follow up
defined as adequate). We assessed each criterion (except blinding)
as adequate, inadequate, or unclear according to Juni 2001.
We assessed blinding as double blind (trial uses a placebo or a
double dummy technique such that neither the participant or care
provider/assessor knows which treatment is given), single blind
(participant or care provider/assessor is aware of the treatment
given), or open (all parties are aware of treatment).
Data collection
One reviewer extracted data (HE or JC), and a second reviewer
checked them (PG).Where studies reported the same outcomes in
different ways, we attempted to contact the trial authors for further
information, which might allow us transform and therefore pool
data. HE entered data into Review Manager 4.1. We extracted
data relating to trial and participant characteristics, and outcomes
reported. We intended to extract data to allow an intention-
to-treat analysis (all the participants analysed according to the
intervention to which they were originally allocated whether
they received it or not). This was not possible but may be
attempted in future updates. Where the numbers randomized
and the numbers analysed for each outcome were inconsistent,
we calculated the percentage loss to follow up and recorded this
information in a table for methodological quality (Table 01).
For binary outcomes, we recorded the number of participants
experiencing the event in each group of the trial. For continuous
outcomes, we extracted arithmetic means and standard deviations.
Where geometric means were reported, we extracted and recorded
this information. We also tried to extract confidence intervals or
standard deviations on the log scale.
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Data analysis
We grouped studies by the main comparator interventions, for
example, albendazole versus placebo. Within comparator groups,
we stratified trials into studies of treatment in individuals and
studies of mass treatment in communities. Within individual and
cluster randomized groups, we combined trials in a meta-analysis,
if appropriate, using a fixed effect model and ReviewManager 4.2.
We calculated relative risks (RR) for binary outcomes and used
95% confidence intervals.
We report medians and ranges in tables only. We assessed
heterogeneity by visually inspecting forest plots and carrying out
a chi-squared test for heterogeneity (statistical significance at 10%
level). We used the random effects model to pool data where
we detected heterogeneity. If no heterogeneity was detected we
used a fixed effect model. Too few trials were available to examine
heterogeneity in any more detail, but this might be possible in
future updates.
D E S C R I P T I O N O F S T U D I E S
Study selection
We identified 146 papers from the search strategies. Seven were
published trials. Of these, we included four, which are described
below and detailed in the ’Characteristics of included studies’ (Sri
Lanka (Jaya1993); Haiti (Beach 1999); Ghana (Dunyo 2000);
India (Pani 2002)), and excluded three (Ismail 1998; Shenoy 1999;
Shenoy 2002) (five publications, see ’Characteristics of excluded
studies’). We excluded two trials because the comparison groups
did not address this question, and one because it was a safety study
carried out only in patients with no detectable microfilariae.
Study design
All studies were randomized, and the unit of randomization for
each trial was the individual.
The length of the follow up varied from 4 months (Haiti (Beach
1999)) to 12 months (Ghana (Dunyo 2000); India (Pani 2002))
to 19 months (Sri Lanka (Jaya1993)).
Participants
A total of 2473 children and adults were randomized in the
four trials, of whom 536 had detectable microfilariae. Sri Lanka
(Jaya1993) and India (Pani 2002) enrolled people who were mi-
crofilariae positive and asymptomatic, Ghana (Dunyo 2000) and
Haiti (Beach 1999) enrolled people who were microfilariae posi-
tive or negative at baseline. One study specifically excluded chil-
dren less than six years old and pregnant women (Ghana (Dunyo
2000)).
Intervention
The trials addressed all the pre-specified comparisons: albendazole
alone versus placebo (Haiti (Beach 1999); Ghana (Dunyo 2000)),
albendazole alone versus DEC (Sri Lanka (Jaya1993); India (Pani
2002)), albendazole alone versus ivermectin (Haiti (Beach 1999);
Ghana (Dunyo 2000)), albendazole plus DEC versus DEC (India
(Pani 2002)), and albendazole plus ivermectin versus ivermectin
(Haiti (Beach 1999); Ghana (Dunyo 2000)).
The dose of albendazole (400 mg) was same in all the trials. The
ivermectin doses varied from 200 to 400 µg/kg in Haiti (Beach
1999) to 150 to 200µg/kg in Ghana (Dunyo 2000). Both India
(Pani 2002) and Sri Lanka (Jaya1993) used the same DEC dose
of 6 mg/kg.
All but one trial gave the drugs as a single treatment; Sri Lanka
(Jaya1993) gave DEC daily and albendazole twice daily for 21
days.
Outcomes
All studies reported on microfilariae. Methods of measurement
varied, including prevalence in 20 µl of blood (Haiti (Beach
1999)), and prevalence and density in 50 µl of blood (India
(Pani 2002)), in 1 ml of blood using membrane filtration (Sri
Lanka (Jaya1993)), or in 100 µl using a counting chamber (Ghana
(Dunyo 2000)). The studies also expressed outcomes differently
(see Characteristics of included studies). All four trials reported
adverse events; none of the included studies determined the effect
of treatment on adult worms by ultrasound scan.
Reported statistical analysis
Standard deviations or confidence intervals were not reported for
microfilarial density outcomes. For this reason, we could not pool
results for changes in microfilarial density; results quoted in this
review are the trial authors’ calculations.
Two of the trials did not clearly describe the method of calculat-
ing reductions in geometric mean microfilarial density (Sri Lanka
(Jaya1993); India (Pani 2002)), but India (Pani 2002) provided
further details on request. This study calculated a William’s mean
(a modification of the geometric mean to include zero counts;
Basanez 1994) on the pretreatment and post-treatment microfi-
larial densities. Ghana (Dunyo 2000) calculated change in micro-
filarial density using both the Williams mean and ’area under the
curve’ analysis (an average intensity over the whole 12month post-
treatment period).
Haiti (Beach 1999) calculated the geometric mean microfilarial
density reduction by dividing the difference between densities be-
fore and after treatment by the pretreatment microfilarial den-
sity and log-transforming the results. If pretreatment microfilarial
density was less than the density after treatment, the reduction
was deemed to be zero. The authors performed this adjustment to
eliminate the problem of log transforming a negative value, but
this method may bias estimates of treatment effectiveness as in-
creases in microfilarial density after treatment are set to zero. For
this reason, we present the pretreatment and post-treatment geo-
metric means for each arm of their study, and percentage change
using these group means.
5Albendazole for lymphatic filariasis (Review)
Copyright © 2005 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
M E T H O D O L O G I C A L Q U A L I T Y
The details of the methodological quality assessment are available
in Table 01.
Generation of allocation sequence
All trials were described as randomized, but India (Pani 2002) did
not describe amethodof randomization, and Sri Lanka (Jaya1993)
only stated that the list was predetermined and restricted.
Allocation concealment
Allocation was concealed in Haiti (Beach 1999) and India (Pani
2002) by using a third party in the allocation process, but was
unclear in the other trials.
Blinding
Three of the trials were double blind (Ghana (Dunyo 2000); Haiti
(Beach 1999); India (Pani 2002)), but blindingwas notmentioned
in the fourth study (Sri Lanka (Jaya1993)).
Completeness of follow up
Losses to follow up were significant in three of the studies. In
Ghana (Dunyo 2000), 1181 (82.9%) of the 1425 participants
were re-examined at 12 months. Losses were similar in the 340 mi-
crofilariae-positive participants enrolled in this study, 67 of these
(20%) were lost to follow up. Haiti (Beach 1999) excluded 380
out of 965 randomized participants (39%) who did not have both
pretreatment and post-treatment blood examinations. However,
there were few losses (n = 3) among the 113 microfilariae-positive
participants at baseline. In Sri Lanka (Jaya1993), 6 of 16 men al-
located to albendazole (37.5% lost to follow up), and 3 of 13 to
DEC (23% lost to follow up) were lost to follow up by 15 to 19
months. India (Pani 2002) reported no losses to follow up.
R E S U L T S
Albendazole versus placebo
In all participants (both microfilariae positive or negative at
baseline)
Microfilaraemia
Haiti (Beach 1999) did not detect a statistical difference in preva-
lence of microfilaraemia for albendazole (22/145) versus placebo
(20/139) (RR 1.05, 95% CI 0.60 to 1.84; Graph 01-01).
Antigenaemia prevalence
Ghana (Dunyo2000) reportedno statistical difference in the num-
bers circulating filarial antigen positive at baseline or 12 months
(albendazole 105 at baseline, 110 at 12 months; placebo 103 at
baseline, 102 at 12 months).
Clinical disease
At 12 months post-treatment Ghana (Dunyo 2000) detected no
statistical difference in the development of hydrocoele between al-
bendazole (1/129) and placebo (1/126) (RR 0.98, 95%CI 0.06 to
15.45; Graph 01-02). No new cases of acute filariasis and leg lym-
phoedema were observed. Similarly, there were no differences in
improvement of symptoms in lymphoedema between the alben-
dazole group (3/13) and placebo group (2/9) (RR 1.04, 95% CI
0.22 to 5.01; Graph 01-03), or in hydrocoele between the alben-
dazole group (3/8) and placebo group (5/10) (RR 0.75, 95% CI
0.25 to 2.23; Graph 01-03). No statistically significant differences
were detected, but the studies lacked power for clinical outcomes,
so clinically important differences cannot be ruled out.
Adverse events
Ghana (Dunyo 2000) did not detect a difference in systemic ad-
verse events between the albendazole group (31/336) compared to
placebo group (33/314) (RR 0.88, 95% CI 0.55 to 1.40; Graph
01-04). No local or severe adverse events were reported. Table 06
displays frequency of specific adverse events.
In participants microfilariae positive at baseline (microfilariae
negative excluded)
Microfilaraemia
Haiti (Beach 1999) found no difference in prevalence between al-
bendazole (22/29) and placebo (20/29) at four months (RR 1.10,
95% CI 0.80 to 1.51). Similarly, Ghana (Dunyo 2000) found no
difference in prevalence at 12 months (62/71 albendazole, 62/66
placebo) (RR 0.93, 95% CI 0.83 to 1.04). A combined estimate
from these two trials shows no difference in microfilaraemia be-
tween albendazole and placebo (RR 0.97, 95% CI 0.87 to 1.09,
n = 195; Graph 01-05).
Microfilarial density (percentage reduction)
Haiti (Beach 1999) estimated the reduction in geometricmeanmi-
crofilarial density. The reductions were 63.8% (14.1 to 5.1) in the
albendazole group, and 43.0% (9.3 to 5.3) in the placebo group at
four months (not statistically significant). Ghana (Dunyo 2000)
reported geometric mean microfilarial density at baseline and 12
months (with percentage reduction). The density decreased from
798 to 251 (68.5%) in the albendazole group compared to 971
to 845 (13.0%) in the placebo group, but this was not statistically
significant (P = 0.10). An ’area under the curve’ analysis from this
study found an increase in microfilariae geometric mean intensity
in the placebo group from 2536 to 2740 (8.4% increase), and a
decrease in the albendazole group from 1535 to 1233 (19.7%);
again this was not statistically significant (P = 0.12). The latter
analysis was limited to those with complete data collection andmi-
crofilarial density of over 100 microfilariae/µl at baseline (seeTable
04).
Antigen density (percentage change)
Ghana (Dunyo 2000) reported that reported that unit geometric
mean microfilarial density (measured by circulating filarial anti-
gen) had increased by 47.5% of the pretreatment level in the
placebo group, but decreased to 83.1% of the pretreatment level
in the albendazole group, but this difference was not statistically
significant (P = 0.11) (Table 05).
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Albendazole versus ivermectin
In all participants (both microfilariae positive or negative at
baseline)
Microfilaraemia
Haiti (Beach 1999) did not demonstrate a difference in microfi-
larial prevalence at follow up between groups allocated to alben-
dazole (22/145) or ivermectin (20/150) (RR 1.14, 95% CI 0.65
to 1.99; Graph 02-01).
Antigenaemia prevalence
Ghana (Dunyo 2000) reported no difference in the numbers cir-
culating filarial antigen positive at baseline or 12 months (alben-
dazole: 105 at baseline, 110 at 12 months; ivermectin: 99 at base-
line, 101 at 12 months).
Clinical disease
Ghana (Dunyo 2000) found no differences in (1) the risk of de-
veloping hydrocoele in the albendazole (1/129) and ivermectin
(1/133) groups (RR 1.03, 95% CI 0.07 to 16.31; Graph 02-02);
(2) improvements in lymphoedema in the albendazole (3/13) and
ivermectin (2/13) groups (RR 1.50, 95% CI 0.30 to 7.55; Graph
02-03); and (3) improvements in hydrocoele in the albendazole
(3/8) and ivermectin (2/9) groups (RR 1.69, 95%CI 0.37 to 7.67;
Graph 02-03). However, sample sizes were small and confidence
intervals wide.
Adverse events
Ghana (Dunyo 2000) detected no difference in systemic adverse
events between the albendazole (31/336) and ivermectin (36/295)
groups (RR 0.76, 95% CI 0.48 to 1.19; Graph 02-04).
In participants microfilariae positive at baseline (microfilariae
negative excluded)
Microfilaraemia
Haiti (Beach 1999) reports microfilarial prevalence at 4 months
follow up: 22/29 in the albendazole group and 17/28 in the iver-
mectin group (RR 0.80, 95% CI 0.56 to 1.15; Graph 02-05).
Ghana (Dunyo 2000) also reported this outcome: 62/71 in the
albendazole group and 52/70 in the ivermectin group (RR 0.85,
95% CI .72 to 1.00; Graph 02-05). Pooling the two studies, al-
bendazole was slightly worse at clearingmicrofilariae, but this only
just reached statistical significance (RR0.84, 95%CI 0.72 to 0.98;
Graph 02-05).
Microfilarial density (percentage reduction)
Haiti (Beach 1999) reported on the percentage reduction in geo-
metric mean microfilarial density. The values at baseline and four
months follow up (with percentage reductions) were 14.1 and 5.1
(63.8% reduction) for albendazole, and 15.5 to 1.5 (90.2% reduc-
tion) for ivermectin. No test of statistical significance was applied.
Ghana (Dunyo 2000) measured mean values at baseline and 12
months follow up (with percentage reductions). For albendazole,
this was from 798 to 251 (68.5% reduction); and for ivermectin,
from 640 to 124 (80.6% reduction); no statistical significance test
was reported. An ’area under the curve’ analysis from this study
found a decrease in the albendazole group (from 1535 to 1233,
19.7%) and in the ivermectin group (from 1731 to 759, 56.2%).
The latter analysis was limited to those with complete data collec-
tion and microfilarial density of over 100 microfilariae/µl at base-
line (see Table 04).
Antigenaemia density (percentage reduction)
Ghana (Dunyo 2000) reported that unit geometric mean micro-
filarial density (measured by circulating filarial antigen) had de-
creased to 83.1% of the pretreatment level in the albendazole
group, and 70.3% in the ivermectin group (no statistical test ap-
plied) (Table 05).
Albendazole plus ivermectin versus ivermectin
In all participants (both microfilariae positive or negative at
baseline)
Microfilaraemia
Haiti (Beach 1999) estimated a statistically significant 65% re-
duction in microfilarial prevalence for the combination (7/151)
compared to ivermectin alone (20/150) (RR 0.35, 95% CI 0.15
to 0.80; Graph 03-01).
Antigen prevalence
Ghana (Dunyo 2000) reported no difference in the numbers of
participants positive for circulating filarial antigen at baseline or
12 months (albendazole plus ivermectin: n = 121 at baseline, n =
122 at 12 months; ivermectin n = 99 at baseline, n = 101 at 12
months).
Clinical disease
Ghana (Dunyo 2000) found no difference in new cases of hy-
drocoele between the combination treatment (2/147) compared
to ivermectin (1/133) (RR 1.81, 95% CI 0.17 to 19.73; Graph
03-02). This study also observed no differences in improvement
in lymphoedema between the combination (2/13) and ivermectin
(2/13) (RR 1.00, 95% CI 0.16 to 6.07; Graph 03-03), and no
differences between combination treatment (4/10) and ivermectin
(2/9) in hydrocoele (RR 1.80, 95% CI 0.43 to 7.59; Graph 03-
03). Again, the studies were not designed to detect changes in
clinical outcomes, therefore confidence intervals are very wide.
Adverse events
Ghana (Dunyo 2000) recordedmore adverse events with the com-
bination treatment (47/332) compared to ivermectin (36/295),
but this was not statistically significant (RR 1.16, CI 0.77 to 1.74;
Graph 03-04). Table 06 displays the occurrence of specific adverse
events.
In participants microfilariae positive at baseline (microfilariae
negative excluded)
Microfilaraemia
Haiti (Beach 1999) reported a 73% reduction in microfilariae
for the combination of albendazole and ivermectin (4/24) com-
pared to ivermectin alone (17/28) at four months (RR 0.27, 95%
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CI 0.11 to 0.70, random effects model; Graph 03-05). However,
Ghana (Dunyo 2000) found no difference between the combina-
tion (58/75) and ivermectin (52/70) (RR 1.04, 95% CI 0.87 to
1.25, random effects model; Graph 03-05). The pooled RR indi-
cated no significant difference for the combination compared to
ivermectin alone, but the confidence intervals are wide. The RR is
0.57 (95% CI 0.13 to 2.48) using the random effects model and
0.87 (95% CI 0.71 to 1.06) using the fixed effect model (Graph
03-05).
Microfilarial density (percentage reduction)
Haiti (Beach 1999) reported a reduction in geometricmeanmicro-
filarial density in the combination group from 13.7 to 0.3 (97.8%)
compared to 15.5 to 1.5 (90.2%) in the ivermectin group at four
months (P < 0.05). Ghana (Dunyo 2000) reported a reduction
in geometric mean microfilarial density in both groups after 12
months: from 614 to 78 (87.3% reduction) in the combination
group compared to a change from 640 to 124 (80.6% reduction)
in the ivermectin group. This was not statistically significant (P
= 0.80). An ’area under the curve’ analysis from this study found
a decrease in the combination group (from 1280 to 393, 69.3%)
and the ivermectin group (from 1731 to 759, 56.2%); this differ-
ence was not statistically significant (P = 0.26). The latter analysis
was limited to those with complete data collection and microfilar-
ial density of over 100 microfilariae/µl at baseline (see Table 04).
Albendazole versus DEC
Two very small studies compared albendazole to DEC. Sri Lanka
(Jaya1993) compared albendazole (n = 16) to DEC (n = 13) and
attempted to follow up participants for up to 19 months. They re-
ported that all participants in this extended follow up lived nearby
and had received treatment in addition to the study intervention,
but the nature of this is unclear. India (Pani 2002) compared al-
bendazole alone (n = 19) and DEC (n = 17), with albendazole and
DEC co-administered (n = 18). All participants were microfilariae
positive at baseline.
Microfilaraemia
India (Pani 2002) reported no statistically significant difference in
microfilarial prevalence at 360 days (14/19 on albendazole com-
pared to 14/17 on DEC). Sri Lanka (Jaya1993) stated that 85%
of the participants treated with albendazole (numerator and de-
nominator unclear) and 67% of the participants treated withDEC
(8/12) still had detectable microfilariae at six months. At the ex-
tended follow up of 15 to 19 months, 50% of participants in both
groups were microfilariae positive (5/10 on both albendazole and
DEC), but a substantial proportion of participants had been lost
to follow up. The data are displayed graphically but should be
viewed with caution (Graph 04-01).
Antigenaemia prevalence
India (Pani 2002) reported no statistically significant difference in
prevalence of filarial antigenaemia at any point during the study (P
> 0.05). The percentage reduction was 83% on albendazole and
87% on DEC (by immuno-chromatographic card test), and 83%
albendazole and 80% DEC (by Og4C3 (ELISA test kit)) (Table
03).
Microfilarial density (percentage reduction)
India (Pani 2002) reported no statistically significant difference in
percentage reductions in geometric mean microfilarial density at
any of the time points when this was measured (days 3, 7, and
360). The percentage reductions at 360 days compared to pre-
therapy values were 97.4% for albendazole and 89.6% for DEC.
However, microfilarial density appeared to fall faster during the
first 7 days on DEC compared to albendazole (Table 03).
Sri Lanka (Jaya1993) also found large reductions in microfilarial
density at six months for both treatment groups; the geometric
mean microfilarial density had fallen to 1.91% of its initial value
for those treated with albendazole and 0.81% for those treated
with DEC. At the extended follow up (15 to 19 months), there
was no statistically significant difference in the geometric mean
microfilarial densities (3 for albendazole and 2 for DEC) (Table
03). Similarly to India (Pani 2002), microfilarial density appeared
to fall faster during the first 28 days on DEC compared to alben-
dazole.
Antigenaemia density
India (Pani 2002) reported statistically significant reductions in
mean optical antigen density by Og4C3 assay in both groups at
360 days (reduction of 0.41 on albendazole, P < 0.0001 for the pre-
intervention value compared to the post-intervention value, 0.32
onDEC; P < 0.0001 for pre-intervention versus post-intervention
value) (Table 05).
Adverse events
India (Pani 2002) reported no severe adverse events in any group.
Those observed were transient (not lasting beyond 6 days) and
included fever, myalgia, and headache. There was no difference
in the proportion reporting any systemic adverse events between
albendazole (8/19, 42.1%) and DEC (9/17, 52.9%) (RR 0.80,
95% CI 0.40 to 1.59; Graph 04-02). The authors used a score
for assessing adverse reactions. The mean score of adverse reaction
intensity was lower for albendazole (1.8, standard deviation 3.0)
compared to DEC (5.6, standard deviation 7.1) (P < 0.05). How-
ever, the validity and clinical significance of this scoring system is
uncertain. In Sri Lanka (Jaya1993), 11 of 15 participants receiv-
ing the full treatment regiment for albendazole developed “scrotal
syndrome”; this was classified as ’severe’ for two men, moderate
for two, and mild for the other 7. None of the participants on
DEC developed similar symptoms (RR 12.19, 95% CI 0.77 to
194.03; Graph 04-03). One participant on DEC had fever, right
hypochondrial pain, and repeated vomiting, and was withdrawn
from the study. However, the drug doses were much higher in this
trial than in the other three. Participants were given albendazole
twice a day, or DEC once a day for three weeks. All other trials
tested a single dose of albendazole plus DEC or ivermectin.
Albendazole plus DEC versus DEC
8Albendazole for lymphatic filariasis (Review)
Copyright © 2005 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Microfilaraemia
India (Pani 2002) found no statistically significant difference in
microfilarial prevalence at 360 days (13/18 on albendazole plus
DEC compared to 14/17 on DEC; Graph 05-01).
Antigenaemia prevalence
India (Pani 2002) reported no statistically significant difference in
prevalence of filarial antigenaemia at any point during the study (P
> 0.05). The percentage reduction was 75% on albendazole plus
DEC compared to 87% on DEC (by immuno-chromatographic
card test), and 81% on albendazole plus DEC compared to 80%
on DEC (by Og4C3) (Table 03).
Microfilarial density (percentage reduction)
Again, there was no difference in percentage reductions in geo-
metric mean microfilarial density. The percentage reductions at
360 days compared with pre-therapy values were 95.4% for al-
bendazole and 89.6% for DEC (Table 04).
Antigenaemia density
There were statistically significant reductions inmean optical anti-
gen density by Og4C3 assay in both groups at 360 days in India
(Pani 2002) (reduction of 0.40 on albendazole plus DEC, P <
0.0001 for pre-intervention compared to post-intervention value,
0.32 on DEC; P < 0.0001 for pre-intervention versus post-inter-
vention value) (Table 05).
Adverse events
India (Pani 2002) reported no difference in the proportion report-
ing any systemic adverse events between albendazole plus DEC
(11/18, 61.1%) and DEC alone (9/17, 52.9%) (RR 1.15, 95%
CI 0.65 to 2.06; Graph 05-02), or in the mean score of adverse
reaction intensity for albendazole plus DEC (6.7, standard devia-
tion 6.6) compared to DEC alone (5.6, standard deviation 7.1).
D I S C U S S I O N
The review was designed to assess the effects of albendazole alone
or in combination with currently recommended antifilarial drugs,
ivermectin, or DEC. Although the review has considered the ef-
fects of albendazole alone, the main interest and strategy of the
’Global Alliance to Eliminate Lymphatic Filariasis’ is in the ef-
fectiveness of combinations of different antifilarial drugs (Ismail
1998; Shenoy 1999). Of particular interest is the effectiveness
of adding albendazole (thought to be macrofilaricidal) to single
dose regimens of ivermectin (thought to be mainly microfilarici-
dal) or DEC (possibly both microfilaricidal and macrofilaricidal)
(CDS/FIL 1998; Ottesen 1999).
All the included studies were designed primarily to assess the ef-
fectiveness of albendazole to treat individuals; none have explicitly
considered its effects on transmission in whole communities. We
identified only four studies, and most are small. All were described
as randomized but had other important limitations. In particular,
losses to follow up were very high (above 20%) in all studies ex-
cept for India (Pani 2002), and this may lead to imbalances in the
comparison groups. Differences in design (microfilariae-positive
participants only versus microfilariae-positive and microfilariae-
negative participants at baseline, variable outcome measurement
and reporting, and length of follow up) made it difficult to com-
pare the studies. In particular, some trials report outcomes mainly
for those who are microfilariae positive at baseline (Ghana (Dunyo
2000)). Outcomes for all participants in the trial, regardless of
baseline microfilarial status, would be preferable in assessing the
community impact of mass treatment strategies. Only two of the
studies report changes in antigenaemia prevalence or density in
addition to microfilarial prevalence and density (Ghana (Dunyo
2000); India (Pani 2002)). However, there was broad agreement
between changes in both these outcome measures in these two
studies. None of the studies objectively examined the effects of
antifilarial medication on the viability of adult worms. As adult
worms are responsible for the production of microfilariae, the ex-
tent to which antifilarial drugs affect worm viability is an impor-
tant outcome.
Albendazole alonewas not effective in reducingmicrofilarial preva-
lence (Haiti (Beach 1999); Ghana (Dunyo 2000)), or circulat-
ing filarial antigens (Ghana (Dunyo 2000)), compared to placebo.
Ivermectin appears more effective than albendazole in both these
trials, and a meta-analysis indicates a marginal but statistically sig-
nificant 16% reduction in the RR of microfilarial prevalence after
treatment for those who were microfilariae positive at baseline in
favour of ivermectin.
In one trial, the combination of albendazole and ivermectin was
better than ivermectin alone after four months follow up (Haiti
(Beach 1999)), but in the other trial in which this combination
was examined they were about the same after 12 months follow
up (Ghana (Dunyo 2000)). The lack of measurements at similar
intervals made it impossible to know if the results were substan-
tially alike. It is possible that by 12 months microfilariae levels had
risen sufficiently to dampen the actual effect of the drugs in the
Ghana (Dunyo 2000). The dose of ivermectin was also lower in
Ghana (Dunyo 2000) than in Haiti (Beach 1999). Investigators
in the two trials used different techniques to assess microfilariae:
thick film method in 20 µl of blood with measurement at night
in Haiti (Beach 1999); and the counting chamber method in 100
µl of blood with measurement during the day in Ghana (Dunyo
2000).
Two very small trials compared albendazole to DEC (India (Pani
2002); Sri Lanka (Jaya1993)). Neither found any statistically sig-
nificant differences in microfilarial prevalence or density at any
of the time points measured. Sri Lanka (Jaya1993) included an
extended follow up at 15 to 19 months. There was no statisti-
cal difference in microfilarial prevalence or density between the
two groups at this point, but the numbers were very small and a
high proportion had been lost to follow up. India (Pani 2002) also
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found no statistically significant differences between albendazole
alone, DEC alone, and albendazole plus DEC at one year follow
up. Follow up was complete, but this trial lacked statistical power.
Although all trials provided data on geometric mean microfilarial
density, lack of reporting of standard deviations or confidence
intervals made it impossible to include these results in a meta-
analysis. A reduction in geometric mean microfilarial density was
observed for all treatments including placebo, and the reduction
appeared greater for active treatments (albendazole, DEC, and
ivermectin), but tests of statistical significance were not always
carried out or reported.
The effect of treatment on clinical disease was not remarkable in
any of the comparison groups. This is not surprising as effect sizes
for clinical outcomes were small and the studies were not powered
to detect small clinical benefits.
No severe adverse events or localized reactions were reported in
three of the trials (Haiti (Beach 1999); Ghana (Dunyo 2000); In-
dia (Pani 2002)). Sri Lanka (Jaya1993) found a very high inci-
dence of “scrotal syndrome” among those treated with albenda-
zole, but the doses of both albendazole and DEC were very much
higher than in the other trials. One trial reported that people in
the ivermectin group were more likely to report any systemic ad-
verse event compared to albendazole, but this was not significant
(Ghana (Dunyo 2000)). One trial reported a significantly lower
intensity of adverse events in the albendazole group, compared
to DEC, or albendazole combined with DEC, but no statistical
difference in the proportions reporting any adverse events (Ghana
(Dunyo 2000)). The death of worms is associated with the devel-
opment of adverse events, so differences in the reporting of ad-
verse events between albendazole, ivermectin, or DEC groups may
reflect differences in the macrofilaricidal properties of the drugs
(Addiss 2000). However, the studies lack statistical power to iden-
tify differences in reporting of adverse events.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on limited data, the evidence suggests that albendazole alone
is not better than placebo, ivermectin, or DEC at clearing blood
microfilariae. Results from two studies that compared albenda-
zole plus ivermectin to ivermectin alone were inconsistent. There
was little difference in the effects detected with albendazole alone,
DEC alone, or albendazole co-administered with DEC from two
very small studies. All the studies were underpowered to assess the
effects of albendazole − alone or in combination − on morbidity
or adverse events. Five ongoing trials are examining the benefits
of adding albendazole to ivermectin or DEC.
The conclusions of this review are based on trials that have only
randomized and treated individuals. Therefore they should be cau-
tiously extrapolated to large scale, population-based mass drug ad-
ministration programmes.
Implications for research
We found only limited data. Further large well-designed studies
are required. For example, studies to:
• compare the effects of albendazole alone, albendazole plusDEC,
and albendazole plus ivermectin on treating and controlling
lymphatic filariasis;
• measure the impact of albendazole in mass drug administration
campaigns;
• evaluate other interventions (against the parasite or the vector)
to augment mass drug administration.
Complete clearance of blood microfilariae theoretically represents
the most reliable strategy for interrupting transmission. But this
may be difficult to achieve in practice, as apart from DEC, cur-
rently available antifilarial drugs mainly act on microfilariae with
no demonstrable macrofilaricidal activity. A drug that kills both
microfilariae and adults is clearly ideal, and there is an argument
for more research on the effects of antifilarial drugs on the adult
worm. This could be assessed objectively, as with ultrasound de-
tection, on a relatively small number of infected individuals.
It is also not known how low microfilarial densities need to fall
in order to successfully interrupt transmission from the various
vector species. As microfilaraemia is an intermediate outcome re-
flecting infectivity of the human host, it is important to assess
comparative effectiveness of drugs that aim to interrupt transmis-
sion. Techniques for assessing microfilariae in blood and outcome
measures for microfilarial densities need to be standardized with
complete reporting of means and standard deviations.
P O T E N T I A L C O N F L I C T O F
I N T E R E S T
Henry Ejere: The Lymphatic Filariasis Support Centre based in the
Liverpool School of Tropical Medicine paid Henry Ejere’s salary.
The Department for International Development, UK and Glaxo-
SmithKline fund the Lymphatic Filariasis Support Centre. Dr Ad-
diss is an author on one of the trials. Julia Critchley, Paul Garner,
Hellen Gelband, Carrol Gamble: none known.
A C K N OW L E D G E M E N T S
None stated.
10Albendazole for lymphatic filariasis (Review)
Copyright © 2005 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
S O U R C E S O F S U P P O R T
External sources of support
• Department for International Development UK
• GlaxoSmithKline UK
Internal sources of support
• Lymphatic Filariasis Support Centre, Liverpool School of Trop-
ical Medicine UK
R E F E R E N C E S
References to studies included in this review
Ghana (Dunyo 2000) {published data only}
∗Dunyo SK, Nkrumah FK, Simonsen PE. Single-dose treatment
of Wuchereria bancrofti infections with ivermectin and albendazole
alone or in combination: evaluation of the potential for control at 12
months after treatment. Transactions of the Royal Society of Tropical
Medicine and Hygiene 2000;94(4):437–43.
Dunyo SK,Nkrumah FK, Simonsen PE. A randomized double-blind
placebo-controlled field trial of ivermectin and albendazole alone and
in combination for the treatment of lymphatic filariasis in Ghana.
Transactions of the Royal Society of TropicalMedicine andHygiene2000;
94(2):205–11.
Dunyo SK, Simonsen PE. Ivermectin and albendazole alone and in
combination for the treatment of lymphatic filariasis. Transactions of
the Royal Society for Tropical Medicine and Hygiene 2002;96(2):189–
92.
Haiti (Beach 1999) {published data only}
Addiss DG, BeachMJ, Streit TG, Lutwick S, LeConte FH, Lafontant
JG, et al. Randomised placebo-controlled comparison of ivermectin
and albendazole alone and in combination for Wuchereria bancrofti
microfilaraemia in Haitian children. Lancet 1997;350(9076):480–4.
∗BeachMJ, Streit TG, Addiss DG, Prospere R, Roberts JM, Lammie
PJ. Assessment of combined ivermectin and albendazole for treat-
ment of intestinal helminth and Wuchereria bancrofti infections in
Haitian school children. American Journal of Tropical Medicine and
Hygiene 1999;60(3):479–86.
India (Pani 2002) {published data only}
Pani SP, Reddy GS, Das LK, Vanamail P, Hoti SL, Ramesh J, et
al. Tolerability and efficacy of single dose albendazole, diethylcar-
bamazxine citrate (DEC) or co-administration of albendazole with
DEC in the clearance of Wucheria bancrofti in asymptomatic mi-
crofilaraemic volunteers in Pondicherry, South India: a hospital-base
study. Filaria Journal 2002;1:1.
Sri Lanka (Jaya1993) {published data only}
Jayakody RL, De Silva CS, Weerasinghe WM. Treatment of ban-
croftian filariasis with albendazole: evaluation of efficacy and adverse
reactions. Tropical Biomedicine 1993;10:19–24.
References to studies excluded from this review
Dunyo 2002
Dunyo SK, Simonsen PE. Ivermectin and albendazole alone and
in combination for the treatment of lymphatic filariasis in Ghana:
follow-up after re-treatment with the combination. Transaction of the
Royal Society of Tropical Medicine and Hygiene 2002;96(2):189–92.
Ismail 1998
∗Ismail MM, Jayakody RL, Weil GJ, Nirmalan N, Jayasinghe KS,
Abeyewickrema W, et al. Efficacy of single dose combinations of
albendazole, ivermectin and diethylcarbamazine for the treatment
of bancroftian filariasis. Transactions of the Royal Society of Tropical
Medicine and Hygiene 1998;92(1):94–7.
Ismail 2001
Ismail MM, Jayakody RL, Weil GJ, Fernando D, De Silva MSG,
De Silva GAC, et al. Long-term efficacy of single-dose combinations
of albendazole, ivermectin and diethylcarbamazine for the treatment
of bancroftian filariasis. Transactions of the Royal Society of Tropical
Medicine and Hygiene 2001;95(3):332–5.
Shenoy 1999
Shenoy RK, Dalia S, John A, Suma TK, Kumaraswami V. Treatment
of the microfilaraemia of asymptomatic brugian filariasis with single
doses of ivermectin, diethylcarbamazine or albendazole, in various
combinations. Annals of Tropical Medicine and Parasitology 1999;93
(6):643–51.
Shenoy 2000
Shenoy RK, John A, Babu BS, Suma TK, Kumaraswami V. Two-
year follow-up of the microfilaraemia of asymptomatic brugian filar-
iasis, after treatment with two, annual, single doses of ivermectin, di-
ethylcarbamazine and albendazole, in various combinations. Annals
of Tropical Medicine and Parasitology 2000;94(6):607–14.
Shenoy 2002
Shenoy RK, Suma TK, John A, Arun SR, Kumaraswami V, Fleck-
enstein LL, et al. The pharmacokinetics, safety and tolerability of
the co-administration of diethylcarbamine and albendazole. Annals
of Tropical Medicine and Parasitology 2002;96(6):603–14.
References to studies awaiting assessment
Simonsen 2004
Simonsen PE, Magesa SM, Dunyo SK, Malecela-Lazaro MN,
Michael E. The effect of single dose ivermectin alone or in combina-
tion with albendazole on Wuchereria bancrofti infection in primary
11Albendazole for lymphatic filariasis (Review)
Copyright © 2005 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
school children in Tanzania. Transactions of the Royal Society of Trop-
ical Medicine and Hygiene 2004;98(8):462–72.
References to ongoing studies
Beach (ongoing)
No details.. Ongoing study No details..
Beach MJ.
Dahoma (ongoing)
Assessment of safety and efficacy of ivermectin and albendazole co-
administration.. Ongoing study No details..
Das (ongoing)
Cluster randomized trial of ivermectin, DEC, and albendazole.. On-
going study No details..
Kshirsagar (ongoing)
Assessment of safety, tolerability, efficacy, and population pharma-
cokinetics of diethylcarbamazine and albendazole co-administration
in a field study in India.. Ongoing study No details..
Makunde (ongoing)
Assessment of safety, tolerability, and efficacy of albendazole alone
or in combination with ivermectin in Tanzania.. Ongoing study No
details..
Makunde WH, Kamugisha LM, Massaga JJ, Salum FM, Makunde
RW, Savael ZX, Akida J, Salum FM, Taylor MJ. Treatment of co-
infection with bancroftian filariasis and onchocerciasis: a safety and
efficacy study of albendazole with ivermectin compared to treatment
of single infection with bancroftian filariasis. Filaria Journal In press.
Additional references
Addiss 2000
Addiss D, Dreyer G. Treatment of lymphatic filariasis. In: Nutman
BT, editor(s). Lymphatic filariasis. London: Imperial College Press,
2000:151–99.
Andrade 1995
Andrade LD, Medeiros Z, Pires ML, Pimentel A, Rocha A,
Figueredo-Silva J, et al. Comparative efficacy of three different di-
ethylcarbamazine regimens in lymphatic filariasis. Transactions of the
Royal Society of Tropical Medicine and Hygiene 1995;89(3):319–21.
Barat 1997
Barat LM, Bloland PB. Drug resistance among malaria and other
parasites. Infectious Disease Clinics of North America 1997;11:969–
87.
Basanez 1994
BasanezMG, BoussinesqM, Prod’hon J, FrontadoH, Villamizar NJ,
Medley GF, et al. Density-dependent processes in the transmission of
human onchocerciasis: intensity of microfilariae in the skin and their
uptake by the simuliid host. Parasitology 1994;108(Pt 1):115–27.
Burkot 2002
Burkot TR, Taleo G, Toeaso V, Ichimoir K. Progress towards, and
challenges for, the elimination of filariasis from Pacific-island com-
munities.Annals of TropicalMedicine and Parasitology 2002;96 Suppl
2:61–9.
Cao 1997
Cao WC, Van der Ploeg CP, Plaisier AP, van der Sivera Sluijs IJ,
Habbema JD. Ivermectin for the chemotherapy of bancroftian filaria-
sis: a meta-analysis of the effect of single treatment. TropicalMedicine
and International Health 1997;2(4):393–403.
Cartel 1990
Cartel JL, Sechan Y, Boutin JP, Celerier P, Plichart R, Roux JF. Iver-
mectin for treatement of bancroftian filariasis French Polynesia: ef-
ficacy in man, effect on transmission by vector Aedes polynesiensis.
Tropical Medicine and Parasitology 1990;41(3):241–4.
CDS/FIL 1998
Filariasis Elimination Programme (CDS/FIL) Division of Control
of Tropical Diseases, Communicable Diseases. Report from informal
consultation on albendazole research findings in lymphatic filariasis
(closed document). Geneva: World Health Organization, 1998.
Clarke 2003
Clarke M, Oxman A, editors. Optimal search strategy. Cochrane
Reviewers’ Handbook 4.2 [updated March 2003]; Appendix 5C.
In: The Cochrane Library. The Cochrane Collaboration. Chichester,
UK: John Wiley & Sons, Ltd; 2003, issue 3
Coutinho 1994
CoutinhoAD,DreyerG,Medeiros Z, Lopes E,MachadoG,Galdino
E, et al. Ivermectin treatment of bancroftian filariasis in Recife, Brazil.
American Journal of Tropical Medicine and Hygiene 1994;50(3):339–
48.
Dreyer 1994
Dreyer G, Pires ML, Andrade LD, Lopes E, Medeiros Z, Tenorio J,
et al. Tolerance of diethylcarbamazine by microfilaraemic and ami-
crofilaraemic individuals in an endemic area of Bancroftian filariasis,
Recife, Brazil. Transactions of the Royal Society of Tropical Medicine
Hygiene 1994;88(2):232–6.
Dreyer 1995
Dreyer G, Amaral F, Noroes J, Medeiro Z, Addiss D. A new tool to
assess in vivo the adulticidal efficacy of antifilarial drugs for bancrof-
tian filariasis.Transactions of the Royal Society of TropicalMedicine and
Hygiene 1995;89(2):225–6.
Dreyer 1996
Dreyer G, Addiss D, Noroes J, Amaral F, Rocha A, Coutinho A. Ul-
trasonographic assessment of the adulticidal efficacy of repeat high-
dose ivermectin in bancroftian filariasis. Tropical Medicine and Inter-
national Health 1996;1(4):427–32.
Dreyer 2000
Dreyer G, Noroes J, Figueredo-Silva, Piessens WF. Pathogenesis of
lymphatic disease in bancroftian filariasis: a clinical perspective. Par-
asitology Today 2000;16(12):544–8.
Eberhard 1989
Eberhard ML, Lammie PJ, Roberts JM, Lowrie RC Jr. Effective-
ness of spaced doses of diethylcarbamazine citrate for the control of
bancroftian filariasis. Tropical Medicine and Parasitology 1989;40(2):
111–3.
FGN 1996
The Filarial Genome Network. Biology and epidemiology of filarial
nematodes. http:
//www.math.smith.edu/~sawlab/fgn/pnb/filbio.html 1996 (accessed
3 September 2001).
Figueredo-Silva 1996
Figueredo-Silva J, Jungmann P, Noroes J, Piessens WF, Coutinho
A, Brito C, et al. Histological evidence for adulticidal effect of low
12Albendazole for lymphatic filariasis (Review)
Copyright © 2005 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
doses of diethylcarbamazine in bancroftian filariasis. Transactions of
the Royal Society of TropicalMedicine and Hygiene 1996;90(2):192–4.
Geerts 2001
Geerts S, Gryseels B. Anthelmintic resistance in human helminths: a
review. Tropical Medicine and International Health 2001;6(11):915–
21.
Gelband 1994
Gelband H. Diethylcarbamazine salt in the control of lymphatic
filariasis. American Journal of Tropical Medicine 1994;50(6):655–62.
GSK 2003
GlaxoSmithKline. Lymphatic filariasis programme: eliminating lym-
phatic filariasis. www.gsk.com/filariasis/eliminating.htm (accessed
October 2002).
Horton 2000
Horton J. Albendazole: a review of anthelmintic efficacy and safety
in humans. Parasitology 2000;121 Suppl:113–32.
Juni 2001
Juni P, Altman DG, Egger M. Systematic reviews in health care: As-
sessing the quality of controlled clinical trials. BMJ 2001;323(7303):
42–6.
Mahoney 1971
Mahoney LE, Kessel JF. Treatment failure in filariasis mass treatment
programmes. Bulletin of the World Health Organization 1971;45(1):
35–42.
Meyrowitsch 1995
Meroywitsch DW, Simonsen PE, Makunde WH. A 16-year follow-
up study on bancroftian filariasis in three communities of north-
eastern Tanzania. Annals of Tropical Medicine and Parasitology 1995;
89(6):665–75.
Michael 1996
Michael E, Bundy DAP, Grenfell BT. Re-assessing the global preva-
lence and distribution of lymphatic filariasis. Parasitology 1996;112
(Pt 4):409–28.
Noroes 1997
Noroes J, Dreyer G, Santos A, Mendes VG, Medeiros Z, Addiss D.
Assessment of the efficacy of diethylcarbamazine on adultWuchereria
bancrofti in vivo. Transactions of the Royal Society Tropical Medicine
and Hygiene 1997;91(1):78–81.
Ottesen 1997
Ottesen EA, Duke BOL, Karam M, Behbehani K. Strategies and
tools for the control/elimination of lymphatic filariasis. Bulletin of
the World Health Organization 1997;75(6):491–503.
Ottesen 1999
Ottesen EA, Ismail MM, Horton J. The role of albendazole in pro-
grammes to eliminate lymphatic filariasis. Parasitology Today 1999;
15(9):382–6.
Pichon 2002
Pichon G. Limitation and facilitation in the vectors and other aspects
of the dynamics of filarial transmission: the need for vector control
against Anopheles-transmitted filariasis. Annals of Tropical Medicine
and Parasitology 2002;96 Suppl 2:143–52.
Review Manager 4.1
. Review Manager (RevMan). 4.1 for Windows Edition. Oxford,
England: The Cochrane Collaboration, 2000. CD-ROM and Inter-
net.
Review Manager 4.2
. Review Manager (RevMan). 4.2 for Windows Edition. Oxford,
England: The Cochrane Collaboration, 2002. CD-ROM and Inter-
net.
Scott 2000
Scott AL. Lymphatic-dwelling filariae. In: Nutman BT, editor(s).
Lymphatic filariasis. London: Imperial College Press, 2000:5–39.
Simonsen 1995
Simonsen PE, Meyrowitsch DW, Makunde WH, Magnussen P. Se-
lective diethylcarbamazine chemotherapy for control of bancroftian
filariasis in two communities of Tanzania: compared efficacy of a
standard dose treatment and two semi-annual single dose treatments.
American Journal of Tropical Medicine and Hygiene 1995;53(3):267–
72.
Simonsen 1997
Simonsen PE, Niemann L, Meyrowitsch DW. Wuchereria bancrofti
in Tanzania: microfilarial periodicity and effect of blood sampling
time on microfilarial intensities. Tropical Medicine and International
Health 1997;2(2):153–8.
Taylor 2001
Taylor MJ, Cross HF, Ford L, Makunde W, Prasad GBKS, Bilo
K. Wolbachia bacteria in filarial immunity and disease. Parasite im-
munology 2001;23(7):401–9.
Vanamail 1990
Vanamail P, Subramanian S, Das PK, Pani SP, Rajagopalan PK. Es-
timation of fecundic life span of Wuchereria bancrofti from longitu-
dinal study of human infection in an endemic area of Pondicherry
(south India). Indian Journal of Medical Research 1990;91:293–7.
Weil 1997
Weil GJ, Lammie PJ, Weis N. The ICT filariasis test: a rapid-format
antigen test for diagnosis of bancroftian filariasis. Parasitology Today
1997;13(10):401–4.
Weil 1999
Weil GJ, Ramzy RM, El Setouhy M, Kandil AM, Ahmed ES, Faris
R. A longitudinal study of Bancroftian filariasis in the Nile Delta
of Egypt: baseline data and one-year follow-up. American Journal of
Tropical Medicine and Hygiene 1999;61(1):53–8.
WHO 1984
WHO Expert Committee on Filariasis. Lymphatic filariasis: fourth
report of the WHO Expert Committee on Filariasis [meeting held in
Geneva from 31 October to 8 November 1983]. Geneva:World Health
Organization, 1984.
WHO 2000
World Health Organization. Lymphatic filariasis. Fact sheet 102.
www.who.int/inf-fs/en/fact102.html 2000 (accessed 3 September
2001).
∗Indicates the major publication for the study
13Albendazole for lymphatic filariasis (Review)
Copyright © 2005 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
T A B L E S
Characteristics of included studies
Study Ghana (Dunyo 2000)
Methods Study design: randomized controlled trial.
Follow up: 12 months.
Method of microfiliarial assessment/volume of blood: microfilariae in 100 µl of finger-prick blood using the
counting chamber technique, daytime collection.
Antigen testing by ELISA from fingerprick blood specimens.
Participants Individuals (male and female) 6 to 87 years with or without Wuchereria bancrofti.
1425 people randomized, of whom 340 microfilariae-positive individuals are followed up.
Interventions (1) Albendazole 400 mg (88 participants).
(2) Ivermectin 150 to 200 µg/kg (79 participants).
(3) Albendazole plus ivermectin (90 participants).
(4) Placebo (83 participants).
Outcomes (1) Number of individuals microfilariae positive at 12 months post-treatment.
(2) Geometric mean microfiliarial density.
(3) Percentage of pretreatment microfilarial concentration.
(4) Geometric mean circulating filarial antigen intensity.
(5) Geometric mean circulating filarial antigen intensity as percentage of pretreatment value.
(6) New infections (appearance of antigenaemia).
(7) New disease events (lymphoedema or hydrocoele).
(8) Mortality during follow up.
Notes Study location: southern Ghana (Butre, Achowa, Adjan, and Miamia villages).
Endemicity level: 18 to 25%.
Adjusted and unadjusted geometric mean microfilarial intensities given.
Standard deviation not reported for geometric mean microfilarial density.
Allocation concealment B
Study Haiti (Beach 1999)
Methods Study design: randomized controlled trial.
Method of microfilarial assessment/volume of blood: thick smear, 20 µl of finger-prick blood.
Participants Children (male and female) 5 to 11 years with Wuchereria bancrofti filariasis.
Number randomized: 965 children, of whom 113 were microfilariae positive.
Interventions (1) Albendazole 400 mg (244 participants).
(2) Ivermectin 200 to 400 µg/kg (240 participants).
(3) Albendazole plus ivermectin (245 participants).
(4) Placebo (229 participants).
Outcomes (1) Post-treatment reduction in percentage microfiliarial prevalence.
(2) Percentage reduction in geometric mean microfilarial density.
(3) Prevalence of Wuchereria bancrofti among all children in each treatment group.
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Characteristics of included studies (Continued )
Notes Study location: Leogane, Haiti.
Endemicity level: not stated.
Standard deviation not reported for geometric mean microfilarial density.
No values reported for the albendazole group in geometric mean microfilarial percentage reduction.
Allocation concealment A
Study India (Pani 2002)
Methods Study design: randomized controlled trial.
Method of microfilarial assessment/volume of blood: not clear, 1 ml venous blood collected between 7:30
and 8:30 pm.
Antigen testing by immuno-chromatographic card test and by Og4C3 ELISA test kit on 50 µl serum.
Participants Asymptomatic volunteers (male and female) between 10 and 57 years, microfilariae positive.
Interventions (1) Albendazole 400 mg (19 participants).
(2) Diethylcarbamazine 6 mg/kg (17 participants).
(3) Albedazole plus diethylcarbamazine (18 participants).
Outcomes (1) Percentage of individuals microfilariae positive post-treatment.
(2) Percentage reduction in geometric mean microfiliarial density.
(3) Percentage reduction in filarial antigen prevalence.
(4) Proportion of individuals reporting any systemic adverse event and intensity of events.
Notes Study location: Pondicherry, India.
Endemicity level: not stated.
No standard deviation reported for geometric mean microfilarial density.
Allocation concealment A
Study Sri Lanka (Jaya1993)
Methods Study design: randomized controlled trial.
Methodofmicrofilarial assessment/volume of blood:membrane filtration formicrofilariae using aNucleopore
filter with a 3 µm pore size.
Participants with mf density in night blood films > 100 microfilariae/ml at least once during previous week
included.
Participants Asymptomatic men aged 18 to 65 years with Wuchereria bancrofti microfilariae.
Interventions (1) Albendazole 400 mg given twice daily for 21 days (16 participants).
(2) Diethylcarbamazine 6 mg/kg daily for 21 days (13 participants).
Outcomes (1) Post-treatment percentage prevalence reduction.
(2) Percentage reduction in geometric mean microfilariae density.
Notes Study location: Colombo, Sri Lanka.
Endemicity level: not stated.
Allocation concealment B
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ELISA: enzyme-linked immunosorbent assay
Characteristics of excluded studies
Study Reason for exclusion
Dunyo 2002 Update of Ghana (Dunyo 2000) following retreatment of each intervention group. Retreatment was only with alben-
dazole plus ivermectin, hence no comparison group received ivermectin alone.
Ismail 1998 The comparison groups - albendazole versus (albendazole plus ivermectin) versus (albendazole plus diethylcarbamazine)
versus (diethylcarbamazine plus ivermectin) - do not meet the inclusion criteria.
Ismail 2001 Same study as Ismail 1998 with continued follow up, and excluded for the same reasons.
Shenoy 1999 The comparison groups - albendazole versus (albendazole plus ivermectin) versus (albendazole plus diethylcarbamazine)
versus (diethylcarbamazine plus ivermectin) - do not meet the inclusion criteria.
Shenoy 2000 Same study as Shenoy 1999 with follow up of individuals from previous study who were retreated. Comparison groups:
(albendazole plus ivermectin) versus (albendazole plus diethylcarbamazine) versus (ivermectin plus diethylcarbamazine).
Shenoy 2002 Study of safety and tolerability of adding albendazole to diethylcarbamazine. Carried out only in patients without
microfilariaemia, that is, presumably uninfected.
Characteristics of ongoing studies
Study Beach (ongoing)
Trial name or title No details.
Participants No details.
Interventions (1) Diethylcarbamazine.
(2) Albendazole.
Outcomes No details.
Starting date No details.
Contact information Michael Beach, CDC US.
mjb3@cdc.gov
Notes
Study Dahoma (ongoing)
Trial name or title Assessment of safety and efficacy of ivermectin and albendazole co-administration.
Participants 1000 participants living in an area endemic for lymphatic filariasis and soil transmitted helminths in Zanzibar,
Tanzania.
Interventions (1) Ivermectin.
(2) Albendazole plus ivermectin.
Outcomes (1) Reappearance of microfilariae at 12 months.
(2) Microfilariae at 3 and 6 months.
(3) Adverse drug reactions.
Starting date No details.
Contact information Mark Bradley,
SmithKline Beecham
GlaxoWellcome House West,
Berkeley Avenue,
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Characteristics of ongoing studies (Continued )
Greenford,
Middlesex UB6 0NN, UK
Phone: +44 (0)208 966 8543
Fax: +44 (0)208 966 8827
E-mail: mhb38319@GlaxoWellcome.co.uk
Notes
Study Das (ongoing)
Trial name or title Cluster randomized trial of ivermectin, DEC, and albendazole.
Participants Villages.
Interventions (1) Ivermectin
(2) Diethylcarbamazine.
(3) Albendazole and diethylcarbamazine.
Outcomes No details.
Starting date No details.
Contact information Dr PK Das vcrc@vsnl.com
Notes
Study Kshirsagar (ongoing)
Trial name or title Assessment of safety, tolerability, efficacy, and population pharmacokinetics of diethylcarbamazine and alben-
dazole co-administration in a field study in India.
Participants 3500 participants infected or healthy in areas endemic for lymphatic filariasis in India.
Interventions (1) Diethylcarbamazine.
(2) Albendazole plus diethylcarbamazine.
Outcomes (1) Microfilariae clearance at 3, 6, and 12 months.
(2) Microfilariae positive at 3, 6, and 12 months.
Starting date No details.
Contact information Mark Bradley,
SmithKline Beecham
GlaxoWellcome House West,
Berkeley Avenue,
Greenford,
Middlesex UB6 0NN, UK
Phone: +44 (0)208 966 8543
Fax: +44 (0)208 966 8827
E-mail: mhb38319@GlaxoWellcome.co.uk
Notes
Study Makunde (ongoing)
Trial name or title Assessment of safety, tolerability, and efficacy of albendazole alone or in combination with ivermectin in Tan-
zania.
Participants 41 participants living in an area endemic for lymphatic filariasis.
Interventions (1) Albendazole.
(2) Albendazole plus ivermectin.
Outcomes (1) Microfilariae counts at 6, 9, and 12 months.
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Characteristics of ongoing studies (Continued )
Starting date No details.
Contact information Mark Taylor, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK
Notes Study in press
The names of principal investigators are used as study ID.
A D D I T I O N A L T A B L E S
Table 01. Assessment of methodological quality
Trial Alloc. sequence Alloc. concealment Blinding Follow up
Ghana (Dunyo 2000) Adequate: computer-
generated
Unclear Double blind: identical
placebos used for each
group
Inadequate: 273
(80%) analysed of 340
microfilarial-positive
participants randomized
Haiti (Beach 1999) Adequate: random-
number table
Adequate: concealed by
third party
“Double blind” stated,
although drugs were not
identical, participants
had no way of identifying
them. Outcome assessors
were blind
Inadequate: 585 analysed
of 965 randomized
(61%)
India (Pani 2002) Unclear Adequate: concealed by
third party
Double blind:
comparable placebo and
outcome assessors blind
Adequate: implies no
losses to follow up (54
analyzed out of 54
randomized)
Sri Lanka (Jaya1993 ) Unclear: predetermined
randomization list
Unclear: states
randomization list
’restricted’
Unclear Inadequate: 20 analysed
of 29 randomized (74%)
Table 02. Microfilaraemia
Study Intervention No. participants +ve at baseline
+ve post-
treatment % of baseline % reduction
Ghana (Dunyo
2000)
Placebo 66 -- 6 months: 62 93.9
” Albendazole 71 -- 6 months: 62 87.3
” Ivermectin 70 -- 6 months: 52 74.3 --
” Albendazole plus
ivermectin
75 -- 6 months: 58 77.3 --
Haiti (Beach
1999)
(only participants
positive for
microfilariae at
baseline)
Placebo 29 -- 4 months: 20 69.0 --
” Albendazole 29 -- 4 months: 22 75.9 --
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Table 02. Microfilaraemia (Continued )
Study Intervention No. participants +ve at baseline
+ve post-
treatment % of baseline % reduction
” Ivermectin 28 -- 4 months: 17 60.7 --
” Albendazole plus
ivermectin
24 -- 4 months: 4 16.7 --
Haiti (Beach
1999)
(Participants
microfilariae
positive or
negative at
baseline)
Placebo 139 25 (18.0%) 4 months: 20
(14.4%)
-- 20.0
” Albendazole 145 26 (17.9%) 4 months: 22
(15.2%)
-- 15.4
” Ivermectin 150 26 (17.3%) 4 months: 20
(13.3%)
-- 23.1
” Albendazole plus
ivermectin
151 19 (12.6%) 4 months: 7
(4.6%)
-- 63.2
India (Pani 2002) Albendazole 19 -- Day 30: none
showed complete
clearance
Day 90: 18
(94.7%)
Day 360: 14
(73.3%)
-- --
” Diethylcarba-
mazine
17 -- Day 30: none
showed complete
clearance
Day 90: 17
(100%)
Day 360: 14
(82.3%)
-- --
” Albendazole plus
diethylcarba-
mazine
18 -- Day 30: none
showed complete
clearance
Day 90: 18
(100%)
Day 360: 13
(72.2%)
-- --
Sri Lanka
(Jaya1993)
Albendazole 16 -- Day 28: 12/15
(80%)
3 months:
denominator
unclear
6 months:
numbers unclear
-- --
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Table 02. Microfilaraemia (Continued )
Study Intervention No. participants +ve at baseline
+ve post-
treatment % of baseline % reduction
(85%)
15 to 19 months:
5/10 (50%)
” Diethylcarba-
mazine
13 -- Day 28: 7/12
(58%)
3 months: 9/12
(75%)
6 months: 8/12
(67%)
15 to 19 months:
5/10 (50%)
-- --
Table 03. Antigenaemia prevalence
Study Outcome measure Intervention No. participants % reduction Baseline 12 months
India (Pani 2002) Antigen positivity
(immuno-
chromatographic
card test on 50 µl
serum)
Albendazole 19 Day 360: 83 -- --
“ ” Diethylcarbamazine 17 Day 360: 87 -- --
“ ” Albendazole plus
diethylcarbamazine
18 Day 360: 75 -- --
” Antigen positivity
(Og4C3 test kit on
50 µl serum)
Albendazole 19 Day 360: 83 -- --
“ ” Diethylcarbamazine 17 Day 360: 80 -- --
“ ” Albendazole plus
diethylcarbamazine
18 Day 360: 81 -- --
Ghana (Dunyo
2000)
Circulating filarial
antigen positive
Albendazole -- -- 105 110
“ ” Ivermectin -- -- 99 101
“ ” Albendazole plus
ivermectin
-- -- 121 122
“ ” Placebo -- -- 103 102
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Table 04. Microfiliarial density
Study
Outcome
measure Intervention
No.
participants Pretreatment Post-treatment* % reduction
Ghana (Dunyo
2000)
Geometric mean
microfilarial
density (mf/100
µl)
Placebo 66 971 845 13.0
“ ” Albendazole 71 798 251 68.5
“ ” Ivermectin 70 640 124 80.6
“ ” Albendazole
plus ivermectin
75 614 78 87.3
” Geometric mean
microfiliarial
density (mf/100
µl) measured by
’area under the
curve’**
Placebo 32 2536 2740 108.4 (8.4%
increase)
“ ” Albendazole 42 1535 1233 19.7
“ ” Ivermectin 33 1731 759 43.8
“ ” Albendazole
plus ivermectin
40 1280 393 69.3
Haiti (Beach
1999)
(only
participants
positive for
microfilariae at
baseline)
Geometric mean
microfilarial
density (mf/20
µl)
Placebo 29 9.3 5.3 17.2 (43.0***)
“ ” Albendazole 29 14.1 5.1 28.7 (63.8***)
“ ” Ivermectin 28 15.5 1.5 76.1 (90.2***)
“ ” Albendazole
plus ivermectin
24 13.7 0.3 98.9 (97.8***)
India (Pani
2002)
Geometric mean
microfilarial
density (mf/50
µl)
Albendazole 19 77.6 (range 22
to 606)
-- Day 3: 8.7
Day 7: 14.1
Day 360: 94.7
“ ” Diethylcarba-
mazine
17 81.3 (range 22
to 542)
-- Day 3: 26.2
Day 7: 36.7
Day 360: 89.6
“ ” Albendazole
plus diethylcar-
bamazine
18 79.4 (range 22
to 223)
-- Day 3: 35.7
Day 7: 45.1
Day 360: 95.4
Sri Lanka Geometric mean Albendazole 16 633 +/- 150 3 1.91 (at 6
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Table 04. Microfiliarial density (Continued )
Study
Outcome
measure Intervention
No.
participants Pretreatment Post-treatment* % reduction
(Jaya1993 ) microfilarial
density (mf/1
ml)
months)
“ ” Diethylcarba-
mazine
13 566 +/- 120 2 0.81% (at 6
months)
FOOTNOTES
*12 months
for ’Ghana
(Dunyo 2000)’,
4 months for
’Haiti (Beach
1999)’, 15 to
19 months
for ’Sri Lanka
(Jaya1993)’
** Only in those
individuals with
over 100 mf/µl
blood before
treatment, and
those examined
at baseline, 3, 6,
and 12 months
***Change in
group geometric
means
Table 05. Antigenaemia density
Study
Outcome
measure Intervention
No.
participants Pretreatment Post-treatment* % reduction
Ghana (Dunyo
2000)
Circulating
filarial antigen
unit (geometric
mean intensity)
Placebo 103 1869 2757 147.5 (47.5%
increase)
“ ” Albendazole 105 1370 1139 83.1
“ ” Ivermectin 99 1689 1187 70.3
“ ” Albendazole
plus ivermectin
121 1404 834 59.4
India (Pani
2002)
Og4C3 test kit
on 50 µl serum
Albendazole 19 0.49 (standard
deviation 0.16)
0.08 (standard
deviation 0.17)
--
“ ” Diethylcarba-
mazine
17 0.39 (standard
deviation 0.21)
0.07 (standard
deviation 0.15)
--
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Table 05. Antigenaemia density (Continued )
Study
Outcome
measure Intervention
No.
participants Pretreatment Post-treatment* % reduction
“ ” Albendazole
plus diethylcar-
bamazine
18 0.47 (standard
deviation 0.18)
0.07 (standard
deviation 0.15)
--
FOOTNOTES
*360 days for
’India (Pani
2002)’
Table 06. Specific adverse events
Study Adverse events Placebo ALB* IVER* ALB + IVER DEC* ALB + DEC
Ghana (Dunyo
2000)
Tactile fever 1/70 (1.4%) 3/80 (3.8%) 6/66 (9.1%) 16/80 (20.0%) -- --
Headache 0/70 (0%) 1/80 (1.3%) 7/66 (10.6%) 14/80 (17.5%) -- --
Muscle/joint
pain
2/70 (2.9%) 3/80 (3.8%) 9/66 (13.6%) 10/80 (12.5%) -- --
Weakness 1/70 (1.4%) 1/80 (1.3%) 4/66 (6.1%) 7/80 (8.8%) -- --
Abdominal pain 1/70 (1.4%) 1/80 (1.3%) 0/66 (0%) 4/80 (5%) -- --
Diarrhoea 2/70 (2.9%) 0/80 (0%) 1/66 (1.5%) 2/80 (2.5%) -- --
Itching 0/70 (0%) 1/80 (1.3%) 2/66 (3.0%) 1/80 (1.3%) -- --
Rash 1/70 (1.4%) 0/80 (0%) 1/66 (1.5%) 1/80 (1.3%) -- --
Haiti (Beach
1999)
(participants
microfilariae
positive at
baseline only)
Self-reported
fever
7/29 (24%) 5/27 (19%) -- -- -- --
Headache 12/29 (41%) 6/27 (22%) -- -- -- --
Myalgias 3/29 (10%) 3/27 (11%) -- -- -- --
Cough 2/29 (7%) 3/27 (11%) -- -- -- --
India (Pani
2002)
Any adverse
reaction (mainly
fever, headache,
myalgia)
-- 42.1% -- -- 52.9% 61.1%
Mean intensity
score** (standard
deviation)
-- 1.8 (3.0) -- -- 5.6 (7.1) 6.7 (6.6)
Sri Lanka
(Jaya1993)
Severe scrotal
syndrome***
-- 2/15 (13%) -- -- 0 --
23Albendazole for lymphatic filariasis (Review)
Copyright © 2005 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Table 06. Specific adverse events (Continued )
Study Adverse events Placebo ALB* IVER* ALB + IVER DEC* ALB + DEC
Scrotal
syndrome - mild,
moderate, or
severe
-- 11/15 (73%) -- -- 0 --
Fever, right
hypochondrial
pain and
repeated
vomiting
-- 0/15 -- -- 1/13 (8%) --
FOOTNOTES
*ALB: alben-
dazole; IVER:
ivermectin;
DEC: diethyl-
carbamazine
**All systemic
adverse reactions
recorded by
assigning score 0
(none), 1 (mild),
2 (moderate), or
3 (severe)
***Mild:
epididymis felt
enlarged and
tender, and
spermatic cord
was tender and
nodular, scrotal
sac swollen;
moderate:
swelling
of scrotal
sac, tender
epididymis,
swelling,
nodularity
or cord, and
some systemic
features, eg fever
malaise; severe:
whole scrotal
sac swollen
and palpation
quite painful,
features of acute
inflammation, eg
redness, warmth,
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Table 06. Specific adverse events (Continued )
Study Adverse events Placebo ALB* IVER* ALB + IVER DEC* ALB + DEC
pain, swelling,
and systemic
features such
as fever, chills,
anorexia, nausea
G R A P H S
Comparison 01. Albendazole versus placebo
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Microfilaraemia in all
participants (both microfilariae
positive or negative at baseline)
Relative Risk (Fixed) 95% CI Subtotals only
02 New clinical disease Relative Risk (Fixed) 95% CI Totals not selected
03 Pre-existing clinical disease Relative Risk (Fixed) 95% CI Totals not selected
04 Adverse events Relative Risk (Fixed) 95% CI Totals not selected
05 Microfilaraemia in participants
microfilariae positive at
baseline (microfilariae negative
excluded)
2 195 Relative Risk (Fixed) 95% CI 0.97 [0.87, 1.09]
Comparison 02. Albendazole versus ivermectin
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Microfilaraemia in all
participants (both microfilariae
positive or negative at baseline)
Relative Risk (Fixed) 95% CI Totals not selected
02 New clinical disease Relative Risk (Fixed) 95% CI Totals not selected
03 Pre-existing clinical disease Relative Risk (Fixed) 95% CI Totals not selected
04 Adverse events Relative Risk (Fixed) 95% CI Totals not selected
05 Microfilaraemia in participants
microfilariae positive at
baseline (microfilariae negative
excluded)
2 198 Relative Risk (Fixed) 95% CI 0.84 [0.72, 0.98]
Comparison 03. Albendazole plus ivermectin versus ivermectin
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Microfilaraemia in all
participants (both microfilariae
positive or negative at baseline)
Relative Risk (Fixed) 95% CI Totals not selected
02 New clinical disease Relative Risk (Fixed) 95% CI Totals not selected
03 Pre-existing clinical disease Relative Risk (Fixed) 95% CI Totals not selected
04 Adverse events Relative Risk (Fixed) 95% CI Totals not selected
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05 Microfilaraemia in participants
microfilariae positive at
baseline (microfilariae negative
excluded)
2 197 Relative Risk (Random) 95% CI 0.57 [0.13, 2.48]
Comparison 04. Albendazole versus DEC
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Microfilaraemia 2 56 Relative Risk (Fixed) 95% CI 0.92 [0.65, 1.30]
02 Adverse events Relative Risk (Fixed) 95% CI Totals not selected
03 Adverse events: scrotal
syndrome
Relative Risk (Fixed) 95% CI Totals not selected
Comparison 05. Albendazole plus DEC versus DEC
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Microfilaraemia Relative Risk (Fixed) 95% CI Subtotals only
02 Adverse events Relative Risk (Fixed) 95% CI Subtotals only
I N D E X T E R M S
Medical Subject Headings (MeSH)
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G R A P H S A N D O T H E R T A B L E S
Comparison 05. 01 Microfilaraemia in all participants (both microfilariae positive or negative at baseline)
Review: Albendazole for lymphatic filariasis
Comparison: 01 Albendazole versus placebo
Outcome: 01 Microfilaraemia in all participants (both microfilariae positive or negative at baseline)
Study Albendazole Placebo Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
Haiti (Beach 1999) 22/145 20/139 100.0 1.05 [ 0.60, 1.84 ]
Subtotal (95% CI) 145 139 100.0 1.05 [ 0.60, 1.84 ]
Total events: 22 (Albendazole), 20 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=0.19 p=0.9
0.2 0.5 1 2 5
Favours albendazole Favours placebo
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Comparison 05. 02 New clinical disease
Review: Albendazole for lymphatic filariasis
Comparison: 01 Albendazole versus placebo
Outcome: 02 New clinical disease
Study Albendazole Placebo Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
01 Hydrocoele
Ghana (Dunyo 2000) 1/129 1/126 0.98 [ 0.06, 15.45 ]
0.01 0.1 1 10 100
Favours albendazole Favours placebo
Comparison 05. 03 Pre-existing clinical disease
Review: Albendazole for lymphatic filariasis
Comparison: 01 Albendazole versus placebo
Outcome: 03 Pre-existing clinical disease
Study Albendazole Placebo Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
01 Improvement in lymphoedema
Ghana (Dunyo 2000) 3/13 2/9 1.04 [ 0.22, 5.01 ]
02 Improvement in hydrocoele
Ghana (Dunyo 2000) 3/8 5/10 0.75 [ 0.25, 2.23 ]
0.1 0.2 0.5 1 2 5 10
Favours albendazole Favours placebo
Comparison 05. 04 Adverse events
Review: Albendazole for lymphatic filariasis
Comparison: 01 Albendazole versus placebo
Outcome: 04 Adverse events
Study Albendazole Placebo Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
01 Systemic adverse events
Ghana (Dunyo 2000) 31/336 33/314 0.88 [ 0.55, 1.40 ]
0.2 0.5 1 2 5
Favours albendazole Favours placebo
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Comparison 05. 05 Microfilaraemia in participants microfilariae positive at baseline (microfilariae negative
excluded)
Review: Albendazole for lymphatic filariasis
Comparison: 01 Albendazole versus placebo
Outcome: 05 Microfilaraemia in participants microfilariae positive at baseline (microfilariae negative excluded)
Study Albendazole Placebo Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
Ghana (Dunyo 2000) 62/71 62/66 76.3 0.93 [ 0.83, 1.04 ]
Haiti (Beach 1999) 22/29 20/29 23.7 1.10 [ 0.80, 1.51 ]
Total (95% CI) 100 95 100.0 0.97 [ 0.87, 1.09 ]
Total events: 84 (Albendazole), 82 (Placebo)
Test for heterogeneity chi-square=1.20 df=1 p=0.27 I =16.5%
Test for overall effect z=0.52 p=0.6
0.5 0.7 1 1.5 2
Favours albendazole Favours placebo
Comparison 05. 01 Microfilaraemia in all participants (both microfilariae positive or negative at baseline)
Review: Albendazole for lymphatic filariasis
Comparison: 02 Albendazole versus ivermectin
Outcome: 01 Microfilaraemia in all participants (both microfilariae positive or negative at baseline)
Study Albendazole Ivermectin Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
Haiti (Beach 1999) 22/145 20/150 1.14 [ 0.65, 1.99 ]
0.1 0.2 0.5 1 2 5 10
Favours albendazole Favours ivermectin
Comparison 05. 02 New clinical disease
Review: Albendazole for lymphatic filariasis
Comparison: 02 Albendazole versus ivermectin
Outcome: 02 New clinical disease
Study Albendazole Ivermectin Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
01 Hydrocoele
Ghana (Dunyo 2000) 1/129 1/133 1.03 [ 0.07, 16.31 ]
0.01 0.1 1 10 100
Favours albendazole Favours ivermectin
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Comparison 05. 03 Pre-existing clinical disease
Review: Albendazole for lymphatic filariasis
Comparison: 02 Albendazole versus ivermectin
Outcome: 03 Pre-existing clinical disease
Study Albendazole Ivermectin Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
01 Improvement in lymphoedema
Ghana (Dunyo 2000) 3/13 2/13 1.50 [ 0.30, 7.55 ]
02 Improvement in hydrocoele
Ghana (Dunyo 2000) 3/8 2/9 1.69 [ 0.37, 7.67 ]
0.1 0.2 0.5 1 2 5 10
Favours albendazole Favours ivermectin
Comparison 05. 04 Adverse events
Review: Albendazole for lymphatic filariasis
Comparison: 02 Albendazole versus ivermectin
Outcome: 04 Adverse events
Study Albendazole Ivermectin Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
01 Systemic adverse effects
Ghana (Dunyo 2000) 31/336 36/295 0.76 [ 0.48, 1.19 ]
0.2 0.5 1 2 5
Favours albendazole Favours ivermectin
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Comparison 05. 05 Microfilaraemia in participants microfilariae positive at baseline (microfilariae negative
excluded)
Review: Albendazole for lymphatic filariasis
Comparison: 02 Albendazole versus ivermectin
Outcome: 05 Microfilaraemia in participants microfilariae positive at baseline (microfilariae negative excluded)
Study Ivermectin Albendazole Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
Ghana (Dunyo 2000) 52/70 62/71 74.0 0.85 [ 0.72, 1.00 ]
Haiti (Beach 1999) 17/28 22/29 26.0 0.80 [ 0.56, 1.15 ]
Total (95% CI) 98 100 100.0 0.84 [ 0.72, 0.98 ]
Total events: 69 (Ivermectin), 84 (Albendazole)
Test for heterogeneity chi-square=0.10 df=1 p=0.76 I =0.0%
Test for overall effect z=2.27 p=0.02
0.5 0.7 1 1.5 2
Favours ivermectin Favours albendazole
Comparison 05. 01 Microfilaraemia in all participants (both microfilariae positive or negative at baseline)
Review: Albendazole for lymphatic filariasis
Comparison: 03 Albendazole plus ivermectin versus ivermectin
Outcome: 01 Microfilaraemia in all participants (both microfilariae positive or negative at baseline)
Study ALB + IVER IVER Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
Haiti (Beach 1999) 7/151 20/150 0.35 [ 0.15, 0.80 ]
0.1 0.2 0.5 1 2 5 10
Favours ALB + IVER Favours IVER
Comparison 05. 02 New clinical disease
Review: Albendazole for lymphatic filariasis
Comparison: 03 Albendazole plus ivermectin versus ivermectin
Outcome: 02 New clinical disease
Study ALB + IVER IVER Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
01 Hydrocoele
Ghana (Dunyo 2000) 2/147 1/133 1.81 [ 0.17, 19.73 ]
0.01 0.1 1 10 100
Favours ALB + IVER Favours IVER
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Comparison 05. 03 Pre-existing clinical disease
Review: Albendazole for lymphatic filariasis
Comparison: 03 Albendazole plus ivermectin versus ivermectin
Outcome: 03 Pre-existing clinical disease
Study ALB + IVER IVER Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
01 Improvement in lymphoedema
Ghana (Dunyo 2000) 2/13 2/13 1.00 [ 0.16, 6.07 ]
02 Improvement in hydrocoele
Ghana (Dunyo 2000) 4/10 2/9 1.80 [ 0.43, 7.59 ]
0.1 0.2 0.5 1 2 5 10
Favours ALB + IVER Favours IVER
Comparison 05. 04 Adverse events
Review: Albendazole for lymphatic filariasis
Comparison: 03 Albendazole plus ivermectin versus ivermectin
Outcome: 04 Adverse events
Study ALB + IVER IVER Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
01 Systemic adverse effects
Ghana (Dunyo 2000) 47/332 36/295 1.16 [ 0.77, 1.74 ]
0.2 0.5 1 2 5
Favours ALB + IVER Favours IVER
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Comparison 05. 05 Microfilaraemia in participants microfilariae positive at baseline (microfilariae negative
excluded)
Review: Albendazole for lymphatic filariasis
Comparison: 03 Albendazole plus ivermectin versus ivermectin
Outcome: 05 Microfilaraemia in participants microfilariae positive at baseline (microfilariae negative excluded)
Study ALB + IVER IVER Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Ghana (Dunyo 2000) 58/75 52/70 54.9 1.04 [ 0.87, 1.25 ]
Haiti (Beach 1999) 4/24 17/28 45.1 0.27 [ 0.11, 0.70 ]
Total (95% CI) 99 98 100.0 0.57 [ 0.13, 2.48 ]
Total events: 62 (ALB + IVER), 69 (IVER)
Test for heterogeneity chi-square=9.46 df=1 p=0.002 I =89.4%
Test for overall effect z=0.75 p=0.5
0.1 0.2 0.5 1 2 5 10
Favours ALB + IVER Favours IVER
Comparison 05. 01 Microfilaraemia
Review: Albendazole for lymphatic filariasis
Comparison: 04 Albendazole versus DEC
Outcome: 01 Microfilaraemia
Study Albendazole DEC Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
India (Pani 2002) 14/19 14/17 74.7 0.89 [ 0.63, 1.27 ]
Sri Lanka (Jaya1993) 5/10 5/10 25.3 1.00 [ 0.42, 2.40 ]
Total (95% CI) 29 27 100.0 0.92 [ 0.65, 1.30 ]
Total events: 19 (Albendazole), 19 (DEC)
Test for heterogeneity chi-square=0.06 df=1 p=0.81 I =0.0%
Test for overall effect z=0.47 p=0.6
0.1 0.2 0.5 1 2 5 10
Favours albendazole Favours DEC
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Comparison 05. 02 Adverse events
Review: Albendazole for lymphatic filariasis
Comparison: 04 Albendazole versus DEC
Outcome: 02 Adverse events
Study Albendazole DEC Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
India (Pani 2002) 8/19 9/17 0.80 [ 0.40, 1.59 ]
0.1 0.2 0.5 1 2 5 10
Favours albendazole Favours DEC
Comparison 05. 03 Adverse events: scrotal syndrome
Review: Albendazole for lymphatic filariasis
Comparison: 04 Albendazole versus DEC
Outcome: 03 Adverse events: scrotal syndrome
Study Albendazole DEC Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
Sri Lanka (Jaya1993) 7/15 0/12 12.19 [ 0.77, 194.03 ]
0.001 0.01 0.1 1 10 100 1000
Favours albendazole Favours DEC
Comparison 05. 01 Microfilaraemia
Review: Albendazole for lymphatic filariasis
Comparison: 05 Albendazole plus DEC versus DEC
Outcome: 01 Microfilaraemia
Study Albendazole + DEC DEC Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
India (Pani 2002) 13/18 14/17 100.0 0.88 [ 0.61, 1.26 ]
Subtotal (95% CI) 18 17 100.0 0.88 [ 0.61, 1.26 ]
Total events: 13 (Albendazole + DEC), 14 (DEC)
Test for heterogeneity: not applicable
Test for overall effect z=0.71 p=0.5
0.1 0.2 0.5 1 2 5 10
Favours ALB + DEC Favours DEC
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Comparison 05. 02 Adverse events
Review: Albendazole for lymphatic filariasis
Comparison: 05 Albendazole plus DEC versus DEC
Outcome: 02 Adverse events
Study ALB + DEC DEC Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
India (Pani 2002) 11/18 9/17 100.0 1.15 [ 0.65, 2.06 ]
Subtotal (95% CI) 18 17 100.0 1.15 [ 0.65, 2.06 ]
Total events: 11 (ALB + DEC), 9 (DEC)
Test for heterogeneity: not applicable
Test for overall effect z=0.48 p=0.6
0.1 0.2 0.5 1 2 5 10
Favours ALB + DEC Favours DEC
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